Yes they used the lower figures from studies in Ibersartan & yes correct Jason, it needs to be taken into consideration when comparing trial results. This can also be a bit tricky when looking at eGFR & overall reduction in risk for ESKD & CVD with SGLT2 class of drugs.
Oct 2, page-13
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $250.5M | |||
| Open | High | Low | Value | Volume |
| 46.5¢ | 47.5¢ | 45.5¢ | $934.4K | 2.015M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 548864 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 35747 | 5 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |